NEW YORK (GenomeWeb) – Amarantus Bioscience Holdings is moving into diagnostics for orphan diseases and today announced it has completed a $5.5 million fundraising round.

The firm's diagnostics division holds the rights to MSPrecise, a proprietary next-generation sequencing assay for identifying patients with relapsing-remitting multiple sclerosis at first clinical presentation; an exclusive worldwide license to the Lymphocyte Proliferation test for Alzheimer's disease; and the intellectual property for NuroPro, a Parkinson's disease diagnostic test.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.